Merck upgrades after strong quarter
On Tuesday, US-based pharmaceutical company Merck (known as MSD outside North America) raised its expectations for financial 2023 after a strong second quarter.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Global pharmaceutical companies are betting big on China
For subscribers